Suchergebnisse - "Gupta, Neeraj"

PubPharm (17)

1

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors : characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

2

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

enthalten in: Haematologica | 2018

von San-Miguel, J. | Echeveste Gutierrez, M. | Špicka, I. | +13

3

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

enthalten in: British journal of haematology | 2018

von Richardson, P. | Hofmeister, C. | Rosenbaum, C. | +15

4

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2018

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

5

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor : Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

enthalten in: Journal of clinical pharmacology | 2018

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +13

6

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

7

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

8

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

enthalten in: Blood | 2017

von Sanchorawala, V. | Palladini, G. | Kukreti, V. | +12

ErratumIn: Blood. 2020 Mar 26;135(13):1071. - PMID 32219354

9

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2016

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +5

10

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

enthalten in: British journal of clinical pharmacology | 2016

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +8